Welcome

Virionyx Corporation is a biopharmaceutical company specialising in the development of immune based therapeutics using its already patented discoveries and proprietary technologies.

Virionyx is a public unlisted biopharmaceutical product development company based in Auckland, New Zealand. The company has two distinct product development platforms. The most advanced platform includes passive immunotherapeutics to human pathogens including HIV, SARS, WNV, and anthrax toxins based on caprine (goat) derived polyclonal antibodies which recognize epitopes that are poorly responded to by the human immune system. The Company’s lead therapeutic candidate, PEHRG214 is an HIV passive immunotherapy currently undergoing Phase 2 trials in the U.S.

Virionyx is developing other immune based therapies which utilize the immuno-reactive properties of a novel proprietary microparticle immune stimulant. 

Current Developments:

Lead Drug Candidate - PEHRG214 represents a new biological approach to the treatment of HIV infected patients who have progressed to AIDS. Currently in US based Phase 2 trials, PEHRG214 is a polyclonal caprine (goat) IgG preparation containing antibodies that target highly conserved regions on HIV not recognised by the human immune system. Existing approved classes of HIV anti-viral drugs, when used in combination, slow down viral replication. In contrast, PEHRG214 specifically targets and destroys multiple clades & strains of the HIV virus.

More >>


Potent Immune Modulator – Virionyx has designed and manufactured a microparticle immune stimulator ("MIS416") which comprises cross linked multiple immunostimulatory TLR and NOD2 ligands that act in a safe, well defined, and synergistic manner. The microparticle is a potent activator of broad innate immune responses. In the presence of an immunogens, the microparticle also amplifies both cellular and humoral adaptive immune responses and thus it is an effective and potent immuno-adjuvant.

More >>


Biodefense Medical Countermeasures - building on both the safety profile established in the Phase 1 trials of PEHRG214, and on the company's microparticle immune stimulator, a range of biodefense related MCM's are in preclinical development.  These include a vaccine and emergency therapies for Anthrax as well an emergency therapy for acute radiation exposure induced neutropenia.

More >>